In conclusion, although the safety profile of FAP-IL2v in combination with pembrolizumab was manageable, the combination showed no added benefit for the treatment of CPI-experienced patients with melanoma who had progressive disease while receiving anti–PD-1 CPI therapy in the previous line of treatment. Here, FAP is linked to melanoma.